Synaptic phosphorylated -synuclein in dementia with Lewy bodies

Citation for published version:

Digital Object Identifier (DOI):
10.1093/brain/awx275

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Brain

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Synaptic phosphorylated α-synuclein in dementia with Lewy bodies

Journal: Brain
Manuscript ID: BRAIN-2017-00849.R1
Manuscript Type: Original Article
Date Submitted by the Author: n/a
Complete List of Authors: Colom-Cadena, Martí; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
Pegueroles, Jordi; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Herrmann, Abbigail; Centre for Cognitive and Neural Systems, Euan MacDonald Centre, and the Centre for Dementia Prevention, University of Edinburgh
Henstridge, Christopher; Centre for Cognitive and Neural Systems, Euan MacDonald Centre, and the Centre for Dementia Prevention, University of Edinburgh
Muñoz-Llahuna, Laia; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
Querol-Vilaseca, Marta; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
Luque-Cabecerans, Joan; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
Clarimon, Jordi; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
Belbin, Olivia; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
Núñez-Llaves, Raúl; Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED
| Blesa, Rafael; Hospital de la Santa Creu i Sant Pau; Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED |
| Smith, Colin; University of Edinburgh, Centre for Clinical Brain Sciences |
| McKenzie, Chris-Anne; University of Edinburgh, Centre for Clinical Brain Sciences |
| Frosch, Matthew; Massachusetts General Hospital and Harvard Medical School |
| Roe, Allyson; Massachusetts General Hospital and Harvard Medical School |
| Fortea, Juan; Hospital de la Santa Creu i Sant Pau; Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED |
| Andilla, Jordi; ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels, Barcelona |
| Loza-Alvarez, Pablo; ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels, Barcelona |
| Gelpi, Ellen; Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS |
| Hyman, Bradley; Massachusetts General Hospital and Harvard Medical School |
| Spires-Jones, Tara; Centre for Cognitive and Neural Systems, Euan MacDonald Centre, and the Centre for Dementia Prevention, University of Edinburgh |
| Lleo, Alberto; Hospital de la Santa Creu i Sant Pau; Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Memory Unit, Department of Neurology; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED |

**Subject category:** Neurodegeneration – cellular and molecular

To search keyword list, use whole or part words followed by an *:

- Neuropathology < DEMENTIA, alpha-Synuclein < NEURODEGENERATION: CELLULAR AND MOLECULAR, Axon degeneration < NEURODEGENERATION: CELLULAR AND MOLECULAR, Lewy bodies < NEURODEGENERATION: CELLULAR AND MOLECULAR, Protein aggregation < NEURODEGENERATION: CELLULAR AND MOLECULAR, Synaptopathy < NEURODEGENERATION: CELLULAR AND MOLECULAR
Synaptic phosphorylated α-synuclein in dementia with Lewy bodies

Martí Colom-Cadena\textsuperscript{1}, Jordi Pegueroles\textsuperscript{1}, Abigail G. Herrmann\textsuperscript{2}, Christopher M. Henstridge\textsuperscript{2}, Laia Muñoz\textsuperscript{1}, Marta Querol-Vilaseca\textsuperscript{1}, Carla San Martin\textsuperscript{1}, Joan Luque-Cabecerans\textsuperscript{1}, Jordi Clarimon\textsuperscript{1}, Olivia Belbin\textsuperscript{1}, Raúl Núñez-Llaves\textsuperscript{1}, Rafael Blesa\textsuperscript{1}, Colin Smith\textsuperscript{4}, Chris-Anne McKenzie\textsuperscript{4}, Matthew P. Frosch\textsuperscript{5}, Allyson Roe\textsuperscript{5}, Juan Fortea\textsuperscript{1}, Jordi Andilla\textsuperscript{6}, Pablo Loza-Alvarez\textsuperscript{6}, Ellen Gelpi\textsuperscript{3}, Bradley T. Hyman\textsuperscript{5}, Tara L. Spires-Jones\textsuperscript{2*}, Alberto Lleó\textsuperscript{1*}

\textsuperscript{1} Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, Barcelona, Spain.
\textsuperscript{2} Centre for Cognitive and Neural Systems, Euan MacDonald Centre, and the Centre for Dementia Prevention, University of Edinburgh, Edinburgh, EH8 9JZ, UK.
\textsuperscript{3} Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Barcelona Spain.
\textsuperscript{4} University of Edinburgh, Centre for Clinical Brain Sciences, Edinburgh, UK.
\textsuperscript{5} Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
\textsuperscript{6} ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels, Barcelona, Spain.

*These authors have contributed equally.

Corresponding author:
Dr. Alberto Lleó
Department of Neurology, Hospital de la Santa Creu i Sant Pau
Sant Antoni Maria Claret, 167
08025 Barcelona, Spain
Phone: +34935565986 ; Fax:+34935565602
Email: alleo@santpau.es

Running title:
Synaptic p-α-synuclein in DLB
Abstract

Dementia with Lewy bodies (DLB) is characterized by the accumulation of Lewy bodies (LB) and Lewy neurites (LN) in the central nervous system, both of which are composed mainly of aggregated α-synuclein phosphorylated at serine 129 (p-α-synuclein). Although phosphorylated α-synuclein is believed to exert toxic effects at the synapse in DLB and other α-synucleinopathies, direct evidence for the precise synaptic localization has been difficult to achieve due to the lack of adequate optical microscopic resolution to study human synapses. In the present study we applied array tomography, a microscopy technique that combines ultrathin sectioning of tissue with immunofluorescence allowing precise identification of small structures, to quantitatively investigate the synaptic p-α-synuclein pathology in dementia with Lewy bodies DLB.

We performed array tomography on human brain samples from the cingulate cortex of 5 dementia with Lewy bodies DLB patients, 5 Alzheimer’s disease patients and 5 healthy controls to analyse the presence of phosphorylated α-synuclein immunoreactivity at the synapse and their relationship with synapse size. Main analyses were performed in blocks from cingulate cortex and confirmed in blocks from the striatum of DLB cases. A total of 1318700 single pre- or post-synaptic terminals were analysed.

We found that p-α-synuclein is present exclusively in dementia with Lewy bodies DLB cases, where it can be identified in the form of Lewy bodies, Lewy neurites LN and small aggregates (<0.16 µm³). 19–25% of phosphorylated α-synuclein deposits were found in pre-synaptic terminals mainly in the form of small aggregates. Synaptic terminals that co-localized with small aggregates of phosphorylated α-synuclein were significantly larger than those that did not. Finally, a gradient of phosphorylated α-synuclein aggregation in synapses (pre>pre+post>post-synaptic) was observed.
These results indicate that phosphorylated$p\alpha$-synuclein is found at the pre-synaptic terminals of dementia with Lewy bodies (DLB) cases mainly in the form of small phosphorylated$p\alpha$-synuclein aggregates that are associated with changes in synaptic morphology. Overall, our data support the notion that pathological phosphorylated$p\alpha$-synuclein may disrupt the structure and function of the synapse in dementia with Lewy bodies (DLB).

**Keywords:** P-$\alpha$-synuclein, Dementia with Lewy bodies, Synapses, Array Tomography, Human tissue.

**Abbreviations:** DLB, dementia with Lewy bodies; LB, Lewy bodies; LN, Lewy neurites; p-$\alpha$-synuclein, $\alpha$-synuclein phosphorylated at serine 129; PSD-95, post-synaptic density protein 95.
Introduction

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer’s disease (AD). The neuropathological hallmark of DLB is the formation of spherical inclusions in the neuronal somata called Lewy bodies (LB) and of elongated structures in dendritic or axonal compartments called Lewy neurites (LN) in the central and peripheral nervous systems (Goedert et al., 2013).

In DLB, Lewy bodies (LBs) and Lewy neurites (LNs) are mainly composed of filaments of misfolded α-synuclein protein (Walker et al., 2015). α-synuclein is a synaptic protein that is located in pre-synaptic terminals where it contributes to neurotransmission and synaptic homeostasis (Maroteaux et al., 1988; Iwai et al., 1995; Clayton and George, 1999; Lashuel et al., 2013; Burré, 2015; Calo et al., 2016). Under pathological conditions α-synuclein is phosphorylated at residue serine 129 (p-α-synuclein). This phenomenon occurs constitutively at very low levels, but is markedly enhanced during pathological processes in which p-α-synuclein is detected in >90% of α-synuclein aggregates (Fujiwara et al., 2002; Hasegawa et al., 2002; Saito et al., 2003; Anderson et al., 2006; Muntané et al., 2012). Growing evidence indicates that aggregation of α-synuclein at synapses is a major event in the pathogenesis of DLB and other α-synucleinopathies (Calo et al., 2016). In particular, data from transgenic animal models suggest a toxic role of α-synuclein in synapses (Garcia-Reitböck et al., 2010; Nemani et al., 2010; Lundblad et al., 2012; Calo et al., 2016). In postmortem brains from patients with DLB, p-α-synuclein is detected in synaptic-enriched fractions (Muntané et al., 2008; Walker et al., 2013) and α-synuclein forms small proteinase-k-resistant aggregates in pre-synaptic terminals (Kramer and Schulz-Schaeffer, 2007; Tanji et al., 2010). These data suggest that, although Lewy bodies (LB) and Lewy neurites (LN) are the classical hallmarks of DLB and other α-synucleinopathies, accumulation of pathological...
α-synuclein at the synapse may be the main effector of the disease leading to synaptic dysfunction and loss. Nonetheless, the study of α-synuclein-mediated synaptic pathology in humans has remained elusive, in part because synapses are small structures difficult to resolve microscopically in human brain.

In the present work we applied array tomography, a technique based on the production of 70nm consecutive sections combined with immunofluorescence, to image synaptic pathology in DLB under the diffraction limit of light (Micheva and Smith, 2007; Kay et al., 2013). Array tomography requires special fixation conditions, which limits the samples available for this type of studies. This technique has been applied previously to successfully demonstrate synaptic abnormalities in animal models of Alzheimer’s disease and in human Alzheimer’s disease brains (Koffie et al., 2009, 2012; Jackson et al., 2016). To our knowledge, this study is the first to use array tomography to quantitatively assess synaptic p-α-synuclein in DLB, which allowed us to resolve α-synuclein pathology in synaptic terminals in human brain samples.
Materials and methods

Standard protocol approvals, and patient consents. All brain donors and/or next of kin had given written informed consent for the use of brain tissue for research. The study was approved by the local ethics committee of: the Hospital de Sant Pau, Barcelona, Spain; the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics committee (approval numbers LR/11/ES/0022, 16/ES/0084, and 15-HV-016; ACCORD is the Academic and Clinical Central Office for Research and Development, a joint office of the University of Edinburgh and NHS Lothian); and the Massachusetts Alzheimer’s Disease Research Centre and Massachusetts General Hospital Neuropathology department with local Institutional Review Board regulations.

Subjects. Human brain samples were obtained from the Edinburgh Brain Bank -see Supplementary Table 1 for Medical Research Council codes-, the Massachusetts Alzheimer’s Disease Research Centre and the Neurological Tissue Bank (NTB) of the Biobanc-Hospital Clinic-IDIBAPS in Barcelona.

Brain sampling and processing protocols for neuropathological diagnoses were carried out following international recommendations as previously described (Colom-Cadena et al., 2013; Kay et al., 2013; Samarasekera et al., 2013).

Fifteen patients fulfilling clinical and neuropathological criteria for DLB (n=5) (McKeith et al., 2005), Alzheimer’s disease (n=5) (Montine et al., 2012), or healthy control cases (n=5) were included in this study. Clinical and neuropathological data were retrospectively obtained from the clinical charts available at the Edinburgh Brain Bank, the Massachusetts Alzheimer’s Disease Research Centre and the NTB. Neuropathological stages were applied according to international recommendations for DLB (McKeith et al., 2005) and Lewy body pathology (Braak et al., 2003). In cases
with concomitant Alzheimer’s disease pathology, current National Institute of Ageing/Alzheimer Association guidelines were applied (Montine et al. 2012).

**Tissue processing for array tomography.** Fresh brain tissue from all cases was processed immediately upon collection for array tomography as previously described (Micheva and Smith, 2007; Kay et al., 2013). The processing was the same for all cases regardless of the collection centre. Briefly, 1mm x 1mm x 3mm tissue blocks from the cingulate cortex comprising all cortical layers and the striatum (nucleus putamen) were sectioned. Tissue blocks were fixed in 4% paraformaldehyde and 2.5% sucrose in 20mM phosphate buffered saline pH 7.4 (PBS) for up to 3 hours. Samples were dehydrated through ascending concentrations of ethanol, embedded into LR White acrylic resin (Electron Microscopy Sciences EMS) and introduced into gelatine capsules where resin was allowed to polymerize overnight at >50°C. After polymerization, tissue blocks were stored at room temperature until used.

**70nm-array production.** LR white embedded tissue blocks were cut at 70nm sections using an ultramicrotome (Leica) equipped with an Ultra Jumbo Diamond Knife 35° (Diatome). Ribbons of at least 30 consecutive sections were produced and collected in gelatine subbed coverslips. For each case, two adjacent blocks of the cingulate cortex were processed as described below (see Fig. 1 for study design).

**Immunofluorescence.** Coverslips with 70nm consecutive sections were stained as previously described (Kay et al., 2013). Sections were incubated with Tris-Glycine solution 5’ at room temperature followed by a blocking of unspecific antigens with a cold water fish blocking buffer (Sigma-Aldrich) for 30 min. Sections were then
incubated for 2 hours with the following primary antibodies: mouse anti-α-synuclein phosphorylated at serine 129 (dilution 1:50, clone P-α-synuclein #64, WAKO), goat anti-synaptophysin (dilution 1:50, AF5555, R&D Systems) and rabbit anti- post-synaptic density protein 95 (-PSD-95) (dilution 1:50, clone D27E11, Cell Signaling), rabbit anti synapsin I (dilution 1:50, AB1543P, Millipore) or rabbit anti--α-synuclein (dilution 1:50, AB5038, Millipore). After Tris buffered salineTBS washings, secondary fluorescent antibodies Alexa 488, Alexa 555 and Alexa 647 (dilution 1:50, Invitrogen) were applied for 30’. Sections were washed with Tris buffered salineTBS and samples were stained with Hoechst 33258 (dilution 1:100, Life Technologies) for 5 min for nuclei visualization. Finally, coverslips were mounted on microscope slides with Immumount (Fisher Scientific) mounting media.

**Image acquisition.** Images of the same region were acquired in consecutive sections using an Olympus BX61 microscope equipped with: 454, 488, 555 and 647 single-band pass filters (49000, 49002, 49004 and 49009 respectively, Chroma); an Orca Flash 4.0 LT camera (Hamamatsu); and a 64x 1.2NA Plan Apochromat objective (Olympus) controlled with HCImage software (Hamamatsu). For Stimulated Emission Depletion microscopy, images from one representative DLB case were acquired using a TCS 5 Stimulated Emission Depletion CW microscope (Leica Microsystems). The CW Stimulated Emission Depletion laser operates at the wavelength of 592 nm and imaging is performed using hybrid detectors. The system performance has been fully characterized and a complete analysis of the achieved transversal resolution can be found elsewhere (Merino et al., 2017). Sections with omission of antibodies or with secondary antibodies only were imaged to ensure specific and independent fluorophore visualization. For co-localization purposes, images were acquired avoiding saturated
pixels. Saturation was only minimally applied for figure visualization. For each case, three fields of each section were imaged comprising all cortical layers (see Fig. 1 for details).

**Image processing and analysis.** Image stacks of each channel comprising all 70nm consecutive sections were first registered as previously described (Kay *et al.*, 2013b) using *Multistackreg 1.4* ImageJ plugin (courtesy of Brad Busse based on (Thévenaz *et al.*, 1998), based on a rigid registration followed by an affine registration of a reference channel that is applied to the other channels. After alignment, identification of immunofluorescent objects and quantification of overlapping objects was achieved using an in-house semi-automatic algorithm (see Fig. 1 for details). Aligned sections were segmented using an automated local thresholding. Additionally, objects that were not in at least two consecutive sections were considered background and removed. Segmentation parameters were exclusive for each channel, but were the same for all included cases. A total of 13187004023248 single pre- or post-synaptic terminals were identified.

After identification of three-dimensional objects, three different analyses were performed: 1) the density of objects for each channel subtracting the area occupied by cell bodies and/or blood vessels using a mask of the maximum intensity projection of the synaptophysin channel; 2) the proportion of channel objects that overlap with objects from another channel; and 3) the median size of all objects and of those co-localizing (see Fig. 1 for details). The in-house semi-automatic algorithm can be freely accessed at https://github.com/MemoryUnitSantPau.
**Experimental design.** The immunostaining, image acquisition, and image processing and analyses were carried out blinded to the clinicopathological diagnosis by assigning a random code to each sample.

**Statistical analysis.** Kruskal-Wallis with uncorrected Dunn’s analysis post-hoc tests were used to compare differences between three groups in p-α-synuclein densities, co-localization percentages or object sizes. Statistical significance was set at 5% (α= 0.05). All data were analysed using the Statistical Package for the Social Sciences version 19.0 (SPSS Inc., Chicago, IL, USA).
Results

Demographic, clinical and neuropathologic characteristics of cases

Demographic, clinical and neuropathologic data are shown in Table 1. As expected, the DLB group exhibited advanced α-synuclein pathology as assessed by McKeith types and Lewy body Braak stages. A group of healthy subjects and Alzheimer’s disease cases were included as controls for the array tomography analyses.

P-α-synuclein is located in DLB pre-synaptic terminals

P-α-synuclein immunoreactivity in DLB was detected in array tomography in the form of Lewy bodies, Lewy neurites as well as small aggregates, the latter being defined as objects <0.16µm^3 without a clear dendritic or axonal morphology (Fig. 2A-B). Occasionally, p-α-synuclein immunoreactivity in cell nuclei was also observed. Quantification of total p-α-synuclein aggregates confirmed that pathology was restricted to DLB in array tomography, with negligible levels in Alzheimer’s disease and controls (Fig. 2C). In contrast, immunofluorescence for non-phosphorylated α-synuclein showed a diffuse punctate pattern in grey matter in both controls and DLB. There was a high degree of overlap between p-α-synuclein and non-phosphorylated α-synuclein in DLB aggregates (Supplementary Fig. 1). Therefore we chose p-α-synuclein as a marker to investigate the synaptic pathology in DLB.

We found that 19.17±4.4% of p-α-synuclein aggregates co-localized with synaptophysin-positive terminals in the cingulate cortex (Fig. 2D, Supplementary Fig. 2, Supplementary Mov. 1). These data were consistent across cases and revealed that most of the p-α-synuclein present at the pre-synapse consisted of small aggregates (76.6±4%), while medium-sized aggregates or Lewy neurites were less abundant (23.4±4%). As expected, no co-localization was found between Lewy bodies and...
synaptic terminals. Of the total synaptophysin-positive synaptic terminals analysed in DLB cases (n= 252696), 2.7±1% contained p-α-synuclein.

The pre-synaptic localization of p-α-synuclein aggregates was confirmed using synapsin I as an additional pre-synaptic marker. We found that 25.9±7.3% of p-α-synuclein aggregates co-localized with synapsin I-positive terminals (Supplementary Fig. 3). As expected, most synapsin I-positive terminals co-localized with synaptophysin.

We used the striatum (putamen) as an additional region to confirm these findings. We found that 19.68±12.7% of p-α-synuclein aggregates in the putamen were co-localizing with synaptophysin-positive pre-synaptic terminals.

Pre-synaptic terminal size and p-α-synuclein aggregation

Synaptic terminals that co-localized with small aggregates of p-α-synuclein were 1.43±0.17-fold larger than those that did not (p=0.014, Fig. 3). Interestingly, this difference was not observed when comparing the size of synaptophysin terminals without p-α-synuclein with those that co-localized with LNs.

Trans-synaptic localization of p-α-synuclein

Trans-synaptic propagation of p-α-synuclein pathology has been proposed as a common mechanism in synucleinopathies (Recasens and Dehay, 2014). To investigate this phenomenon in vivo, we next selected those synaptophysin pre-synaptic terminals that were opposed to objects labelled with the post-synaptic terminal marker PSD-95 (Fig. 4A). In those paired terminals we observed that p-α-synuclein was more frequently located in pre-synaptic terminals (49.82±4.3%, Fig. 4B), followed by a both pre- and post-synaptic localization (33.99±2.4%) and less frequently in the post-synaptic density
only (16.18±3%). The synaptic gradient of p-α-synuclein was also observed in the striatum, with a more pronounced pre-synaptic predominance (70.14±11.2% pre-synaptic-only, 23.13±13.7% pre- and post-synaptic, 6.73±5.2% post-synaptic only). The post-synaptic terminal localization of p-α-synuclein was also confirmed by using Stimulated Emission Depletion microscopy in order to increase the lateral resolution (Fig. 4C). These data confirm that although p-α-synuclein aggregates are preferentially located at the pre-synapse, they can be independently found at the post-synapse as well.
Discussion

In the present study we have shown by array tomography that aggregates of p-α-synuclein were present at the synapse in DLB cases. In pre-synaptic terminals, the majority of p-α-synuclein was found in the form of small aggregates, while other types of aggregates, like Lewy bodies or Lewy neurites, are less abundant. Moreover, these small aggregates were associated with structural changes in pre-synaptic terminals. Finally, we observed a gradient of p-α-synuclein aggregates from the pre- to post-synaptic compartments.

There is growing evidence that synaptic abnormalities in DLB precede neuronal loss and Lewy bodies formation (Chung et al., 2009; Nikolaus et al., 2009; Calo et al., 2016; Henstridge et al., 2016) and that these synaptic defects may bear closely related with clinical symptoms (Vallortigara et al., 2014; Whitfield et al., 2014; Bereczki et al., 2016). However, the investigation of DLB as a primary synaptopathy has been hampered by our technical ability to study synapses in human brain. The small size of synaptic terminals falls under the diffraction limit of light, which limits the use of conventional optical microscopy techniques for this purpose. Electron microscopy, which has been the standard technique to resolve the structure of synapses, only permits the reconstruction of small brain volumes and is less amenable to labelling multiple proteins (O’Rourke et al., 2012).

In the present work we applied array tomography to image synaptic pathology in DLB under the diffraction limit of light (Micheva and Smith, 2007; Kay et al., 2013). To our knowledge, this is the first study to apply array tomography in DLB brains, a technique that has allowed us to perform large-scale quantitative synaptic imaging. We analysed single pre- or post-synaptic terminals together with p-α-synuclein with very high spatial resolution. Previous studies have investigated synaptic proteins in
For Peer Review

DLB brains using conventional immunohistochemistry (Wakabayashi et al., 1994; Revuelta et al., 2008; Scott et al., 2010) or biochemical analysis of brain homogenates (Masliah et al., 1993; Brown et al., 1998; Hansen et al., 1998; Campbell et al., 2000; Reid et al., 2000; Kramer and Schulz-Schaeffer, 2007; Mukaetova-Ladinska et al., 2013; Khundakar et al., 2016; Xing et al., 2016). In some of these studies, p-α-synuclein and proteinase-k resistant α-synuclein aggregates were found in synaptic-enriched fractions (Kramer and Schulz-Schaeffer, 2007; Muntané et al., 2008; Tanji et al., 2010; Walker et al., 2013). However, many of these studies could not specifically address the precise synaptic localization due to the low resolution of the techniques used. Our results confirm and expand on these observations in intact brain samples by using a technique especially suited for the analysis of human brain synapses.

We found that ~20% of p-α-synuclein aggregates were colocalizing with synaptophysin-positive terminals in the cingulate cortex and striatum. The percentage was a slightly higher (25%) when using synapsin I as a presynaptic marker. The detection of p-α-synuclein at pre-synaptic compartments suggests a role in synaptic degeneration. Notably, we found that small α-synuclein aggregates are the most common form in synapses. A previous study (Kramer and Schulz-Schaeffer, 2007) described proteinase-k-resistant aggregates in pre-synaptic compartments that represented the 50-90% of α-synuclein aggregates. We found a much lower percentage of α-synuclein aggregates at the pre-synaptic terminals. This difference may be due to numerous methodological differences: the antibodies used; the methods to detect synapses and pathological aggregates; or our stringent protocol used to define p-α-synuclein and synaptophysin-containing presynaptic objects. Despite these methodological issues, we found that 77% of p-α-synuclein aggregates in contact with
pre-synaptic terminals are small aggregates. Taken together, both studies support the notion of small α-synuclein aggregates as key pathological forms in driving synaptic damage and dysfunction (Schulz-Schaeffer, 2010).

Our results are also in line with the hypothesis that the pre-synaptic terminal is an early site of α-synuclein aggregation in DLB and other α-synucleinopathies, the same site where it is found under physiological conditions (Lashuel et al., 2013; Spinelli et al., 2014; Volpicelli-Daley et al., 2014; Majd et al., 2015; Abellovich and Gitler, 2016). The aggregation of α-synuclein may lead to abnormal functional impairment of neurotransmitter release (Garcia-Reitböck et al., 2010; Nemani et al., 2010), subsequent to axonal transport defects through the impairment of endosome and/or autophagosome transport (Volpicelli-Daley et al., 2014), which may lead to neurodegeneration (Ferrero et al., 2001; Desplats et al., 2009; Decressac et al., 2013).

We also observed larger pre-synaptic terminal volume in the presence of p-α-synuclein. Interestingly, an inverse correlation has been observed between synaptic density and the size of remaining synapses in 

Alzheimer’s disease as measured by the length of the post-synaptic density (DeKosky and Scheff, 1990; Scheff et al., 1990; Scheff and Price, 1993). This enlargement of remaining synapses has been interpreted as a compensatory response, rather than as selective loss of small synapses. Our data could suggest a similar compensatory mechanism in synapses containing pathological p-α-synuclein.

Several previous studies in cellular and animal models have shown that α-synuclein may propagate along neural circuits following a hierarchical pattern (Eisbach and Outeiro, 2013; Masuda-Suzukake et al., 2013; Recasens and Dehay, 2014). The observation of a spatial gradient in p-α-synuclein aggregation in synapses (pre>pre+post>post-synaptic) could be interpreted as a sign of trans-synaptic spreading
of α-synuclein pathology. However, using Stimulated Emission Depletion microscopy we found that although p-α-synuclein predominates at the pre-synapse it can also be found independently at the post-synapse. Due to the inherent descriptive nature of post-mortem studies and the difficulties to identify the synaptic cleft, additional research is needed to elucidate if our findings are related to α-synuclein spreading and/or independent aggregation in both synaptic compartments. Another possible explanation for this observation may be the limited resolution of the technique to clearly dissociate the pre- and post-synapse.

Despite the limitations of our study–relatively small sample size, analysis of a single brain region, inclusion of cases with advanced disease stages, or analysis of a single phospho-epitope of p-α-synuclein–, our findings are important as they demonstrate for the first time that p-α-synuclein accumulates in pre-synaptic terminals by large-scale imaging of synapses in DLB brain. Taken together, the present work provides a visual and quantitative evidence of the synaptic deposition of small p-α-synuclein aggregates in pre-synaptic terminals. This study supports the hypothesis that DLB and other α-synucleinopathies are primary synaptopathies. These data should stimulate the search for therapies aimed at reducing synaptic α-synuclein-induced damage or spread.

Acknowledgments

The authors would like to thank all brain donors and their relatives for generous brain donation for research. This research has been supported by Fundació Cellex Barcelona.
Funding

This work was supported by FISPI14/1561, **Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa”** to A.L., PERIS SLT002/16/00408-01 and Marató TV3 to Alberto Lleó and CIBERNED. Colin Smith and Chris-Anne McKenzie were funded by MRC grant MR/L016400/1. Chris Henstridge is funded by a project grant from MND Scotland. The Massachusetts Alzheimer Disease Research Center is supported by funding from the NIH (P50 AG005134). Tara Spires-Jones is funded by the European Research Council (Consolidator award ALZSYN), Alzheimer’s Research UK, the Scottish Government Chief Scientists’ Office, Alzheimer’s Society, and Wellcome Trust/University of Edinburgh Institutional Strategic Support Funding. Pablo LozafAlvarez is funded by the **Spanish Ministry of Economy and Competitiveness, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV- 2015-0522) and the CERCA Programme/Generalitat de Catalunya**.

Conflict of interest

The authors report no potential conflict of interest. Tara Spires-Jones collaborates with Cognition Therapeutics but this collaboration is not relevant to this study.

References

Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson’s disease pathology


Muntané G, Ferrer I, Martínez-Vicente M. A-Synuclein Phosphorylation and Truncation Are Normal Events in the Adult Human Brain. Neuroscience 2012; 200:


Wakabayashi K, Honer WG, Masliah E. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer’s disease with and without Lewy body disease. Brain


Figure legends

Figure 1. Study design.

Tissue collection and processing of each case is shown in A. For each case, two adjacent tissue sections of cingulate cortex or the striatum (putamen nucleus) were processed and embedded in LR white. For each block a ribbon of >40 consecutive sections of 70nm was produced. Each ribbon was immunostained for synaptophysin (red), p-α-synuclein (green) and PSD-95 (cyan), synapsin I or α-synuclein, and nuclei were visualized with Hoescht 33258 (blue). Three subregions of cortex were imaged through the entire ribbon. In B and C, the processing and analysis of the images is summarized. 1. First, individual channel stacks were produced, with all consecutive sections imaged. Consecutive sections of a reference channel (i.e. synaptophysin) were registered using a rigid and an affine transformation. Transformation matrices were applied to other channels. 2. Second, images were segmented using an in-house algorithm based on local mean threshold segmentation, removing single section objects, filtering by size, and detecting three dimensional objects as 6 neighbour connected components. Raw images (right) and segmented (left) representative images are shown. Each image corresponds to a single 70nm section with its corresponding orthogonal views. 3. Neuropil area was calculated based on a maximum intensity projection of synaptophysin channel. 4. Co-localization between the channels of interest and the sizes of co-localizing objects was calculated. The object density and object size were quantified and 6. For entire synaptic studies, segmented images of synaptophysin (pre-synaptic) and PSD-95 (post-synaptic) channels combined to remove all those objects without pre- and post-synaptic pairs. Abbreviations: Max Int, Maximum intensity; 6n, six neighbour. Scale bar in A and B, 10µm; in C, 2µm.
Figure 2. P-α-synuclein immunoreactivity patterns and synaptic localization.

A Representative images of DLB, control and Alzheimer’s disease cases stained with antibodies against synaptophysin (red) and p-α-synuclein (green). Each image is a maximum intensity projection of 31 consecutive sections. B Representative three-dimensional 3D representations of types of p-α-synuclein aggregates (green) found in DLB cases (green) and synaptophysin terminals (red). Lewy bodies did not co-localize with synaptophysin terminals, while Lewy neurites and small aggregates did (arrowheads). C The quantification of total p-α-synuclein objects revealed that pathology was found almost exclusively in DLB cases (**, p<0.01). D Synaptograms representing six 70nm consecutive sections (from left to right and top to bottom) of the Lewy neurite (LN) or small aggregate (SA) pointed by the arrowheads in B. Are represented both the raw and segmented images are shown. At right, the percentage of pre-synaptic p-α-synuclein found of LN or SA that are pre-synaptic and the percentage of extra-synaptic p-α-synuclein are indicated. Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer disease; LN, Lewy neurite; SA, Small aggregate. Scale bar in A, 10µm; in B, 2µm; in D, 1µm.

Figure 3. Median volume of pre-synaptic terminals co-localizing with p-α-synuclein.

A Three dimensional reconstruction of 20 consecutive sections from a DLB case is shown. P-α-synuclein (green) and synaptophysin (red) are shown. Black arrowheads indicate synaptophysin objects that co-localize with small aggregates of p-α-synuclein, grey arrowheads points to synaptic terminals that co-localize with Lewy neurites, and white arrowheads those synaptophysin objects that do not co-localize with p-α-
synuclein. B Median volumes of synaptic terminals according to co-localization with p-α-synuclein (p-α-synuclein +, or -) and their characteristic pattern (small aggregate or Lewy neurite). Abbreviations: Psyn: Phosphorylated-α-synuclein; SA, small aggregate; LN, Lewy neurite. Scale bar in A, 2µm.

**Figure 4.** Trans-synaptic localization of p-α-synuclein.

A Three dimensional reconstruction of 20 consecutive sections from a DLB case. P-α-synuclein (green), synaptophysin (red) and PSD-95 (blue) are shown. White arrowheads point to zones where p-α-synuclein co-localizes with synaptophysin (pre-synaptic), PSD-95 (post-synaptic) or both (pre and post-synaptic). In B, p-α-synuclein objects that co-localized with synaptic pairs (synaptophysin and PSD-95 objects) are classified depending on its pre-synaptic, pre and post-synaptic or post-synaptic localization. The relative co-localization of p-α-synuclein with the synaptophysin pre-synaptic marker was significantly higher than the PSD-95 post-synaptic co-localization. C A representative reconstruction of synaptic pairs from twenty 70 nm sections from a DLB case. Synaptophysin is shown in red and PSD-95 in cyan. The black square on the left image represents the inset magnified on the right image. At the bottom a synaptogram of ten 70nm consecutive sections is shown. Representative images of the colocalization between between p-α-synuclein, synaptophysin and PSD-95 using array tomography combined with Stimulated Emission Depletion microscopy. A single 70nm-thick section stained for p-α-synuclein (green), synaptophysin (red) and PSD-95 (blue) is shown. Stimulated Emission Depletion was applied to image PSD-95 (upper row) or p-α-synuclein (lower row). Abbreviations: STED, Stimulated Emission Depletion. Scale bar in A, 2µm; in C, 1µm.
Figure 1. Study design.

Tissue collection and processing of each case is shown in A. For each case, two adjacent tissue sections of cingulate cortex or the striatum (putamen nucleus) were processed and embedded in LR white. For each block a ribbon of >40 consecutive sections of 70nm was produced. Each ribbon was immunostained for synaptophysin (red), p-α-synuclein (green) and PSD-95 (cyan), synapsin I or α-synuclein, and nuclei were visualized with Hoechst 33258 (blue). Three subregions were imaged through the entire ribbon. In B and C, the processing and analysis of the images is summarized. 1. First, individual channel stacks were produced. Consecutive sections of a reference channel (i.e. synaptophysin) were registered using a rigid and an affine transformation. Transformation matrices were applied to other channels. 2. Second, images were segmented using an in-house algorithm based on local mean threshold segmentation, removing single section objects, filtering by size, and detecting three dimensional objects as 6 neighbour connected components. Raw images (right) and segmented (left) representative images are shown. Each image corresponds to a single 70nm section with its corresponding orthogonal views. 3. Neuripil area was calculated based on a maximum intensity projection of synaptophysin channel. 4. Co-localization between the channels of interest and the sizes of co-localizing objects was calculated. 5. The...
object density and object size were quantified and 6. For entire synaptic studies, segmented images of synaptophysin (pre-synaptic) and PSD-95 (post-synaptic) channels combined to remove all those objects without pre- and post-synaptic pairs. Abbreviations: Max Int, Maximum intensity; 6n, six neighbour. Scale bar in A and B, 10µm; in C, 2µm.
Figure 2. P-α-synuclein immunoreactivity patterns and synaptic localization.
A Representative images of DLB, control and Alzheimer’s disease cases stained with antibodies against synaptophysin (red) and p-α-synuclein (green). Each image is a maximum intensity projection of 31 consecutive sections. B Representative three dimensional representations of types of p-α-synuclein aggregates (green) found in DLB cases and synaptophysin terminals (red). Lewy bodies did not co-localize with synaptophysin terminals, while Lewy neurites and small aggregates did (arrowheads). C The quantification of total p-α-synuclein objects revealed that pathology was found almost exclusively in DLB cases (**, p<0.01). D Synaptograms representing six 70nm consecutive sections (from left to right) of the Lewy neurite (LN) or small aggregate (SA) pointed by the arrowheads in B. Both the raw and segmented images are shown. The percentage s of pre-synaptic p-α-synuclein found of LN or SA and extra-synaptic p-α-synuclein are indicated. Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer disease; LN, Lewy neurite; SA, Small aggregate. Scale bar in A, 10µm; in B, 2µm; in D, 1µm.
Figure 3. Median volume of pre-synaptic terminals co-localizing with p-α-synuclein.
A Three dimensional reconstruction of 20 consecutive sections from a DLB case is shown. P-α-synuclein (green) and synaptophysin (red) are shown. Black arrowheads indicate synaptophysin objects that co-localize with small aggregates of p-α-synuclein, grey arrowheads point to synaptic terminals that co-localize with Lewy neurites, and white arrowheads those synaptophysin objects that do not co-localize with p-α-synuclein. B Median volumes of synaptic terminals according to co-localization with p-α-synuclein (p-α-synuclein +, or -) and their characteristic pattern (small aggregate or Lewy neurite). Abbreviations: Psyn: Phosphorylated-α-synuclein; SA, small aggregate; LN, Lewy neurite. Scale bar in A, 2µm.
Figure 4. Trans-synaptic localization of p-α-synuclein.

A Three dimensional reconstruction of 20 consecutive sections from a DLB case. P-α-synuclein (green), synaptophysin (red) and PSD-95 (blue) are shown. White arrowheads point to zones where p-α-synuclein co-localizes with synaptophysin (pre-synaptic), PSD-95 (post-synaptic) or both (pre and post-synaptic). In B, p-α-synuclein objects that co-localized with synaptic pairs (synaptophysin and PSD-95 objects) are classified depending on its pre-synaptic, pre and post-synaptic or post-synaptic localization. The relative co-localization of p-α-synuclein with the synaptophysin pre-synaptic marker was significantly higher than the PSD-95 post-synaptic co-localization. C Representative images of the colocalization between between p-α-synuclein, synaptophysin and PSD-95 using array tomography combined with Stimulated Emission Depletion microscopy. A single 70nm-thick section stained for p-α-synuclein (green), synaptophysin (red) and PSD-95 (blue) is shown. Stimulated Emission Depletion was applied to image PSD-95 (upper row) or p-α-synuclein (lower row). Abbreviations: STED, Stimulated Emission Depletion. Scale bar in A, 2µm; in C, 1µm.
**Table 1.** Demographic, clinical and neuropathologic data of control, DLB and \textit{Alzheimer's disease} cases.

<table>
<thead>
<tr>
<th>Case</th>
<th>Diagnosis</th>
<th>Gender</th>
<th>Age at death</th>
<th>PMI (h)</th>
<th>McKeith type</th>
<th>LB Braak stage</th>
<th>Braak NFT stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>M</td>
<td>82</td>
<td>24</td>
<td>-</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>Control</td>
<td>M</td>
<td>63</td>
<td>16</td>
<td>-</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>Control</td>
<td>F</td>
<td>77</td>
<td>75</td>
<td>-</td>
<td>0</td>
<td>I</td>
</tr>
<tr>
<td>4</td>
<td>Control</td>
<td>M</td>
<td>78</td>
<td>39</td>
<td>-</td>
<td>0</td>
<td>I</td>
</tr>
<tr>
<td>5</td>
<td>Control</td>
<td>F</td>
<td>83</td>
<td>8</td>
<td>-</td>
<td>0</td>
<td>II</td>
</tr>
<tr>
<td>6</td>
<td>DLB</td>
<td>M</td>
<td>71</td>
<td>8</td>
<td>Neocortical</td>
<td>5</td>
<td>III</td>
</tr>
<tr>
<td>7</td>
<td>DLB</td>
<td>M</td>
<td>83</td>
<td>24</td>
<td>Neocortical</td>
<td>5</td>
<td>IV</td>
</tr>
<tr>
<td>8</td>
<td>DLB</td>
<td>F</td>
<td>62</td>
<td>9</td>
<td>Neocortical</td>
<td>5</td>
<td>IV</td>
</tr>
<tr>
<td>9</td>
<td>DLB</td>
<td>M</td>
<td>77</td>
<td>36</td>
<td>Neocortical</td>
<td>5</td>
<td>III</td>
</tr>
<tr>
<td>10</td>
<td>DLB</td>
<td>F</td>
<td>83</td>
<td>24</td>
<td>Neocortical</td>
<td>6</td>
<td>VI</td>
</tr>
<tr>
<td>11</td>
<td>AD</td>
<td>M</td>
<td>81</td>
<td>74</td>
<td>-</td>
<td>0</td>
<td>V</td>
</tr>
<tr>
<td>12</td>
<td>AD</td>
<td>M</td>
<td>72</td>
<td>109</td>
<td>-</td>
<td>0</td>
<td>VI</td>
</tr>
<tr>
<td>13</td>
<td>AD</td>
<td>M</td>
<td>81</td>
<td>83</td>
<td>-</td>
<td>0</td>
<td>VI</td>
</tr>
<tr>
<td>14</td>
<td>AD</td>
<td>M</td>
<td>85</td>
<td>91</td>
<td>-</td>
<td>0</td>
<td>VI</td>
</tr>
<tr>
<td>15</td>
<td>AD</td>
<td>F</td>
<td>90</td>
<td>18</td>
<td>-</td>
<td>0</td>
<td>V</td>
</tr>
</tbody>
</table>

Abbreviations: PMI, Post-mortem interval; h, hours; LB, Lewy body; NFT, Neurofibrillary tangle; DLB, dementia with Lewy bodies; AD, Alzheimer disease.
Supplementary Data

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies

Martí Colom-Cadena, Jordi Pegueroles, Abigail G. Herrmann, Christopher M. Henstridge, Laia Muñoz, Marta Querol-Vilaseca, Carla San Martin, Joan Luque-Cabecerans, Jordi Clarimon, Olivia Belbin, Raúl Núñez-Llaves, Rafael Blesa, Colin Smith, Chris-Anne McKenzie, Matthew P. Frosh, Allyson Roe, Juan Fortea, Jordi Andilla, Pablo Loza-Alvarez, Ellen Gelpi, Bradley T. Hyman, Tara L. Spires-Jones, Alberto Lleó

Supplementary Table 1. The Medical Research Council (MRC) Edinburgh Brain & Tissue Bank cases.

<table>
<thead>
<tr>
<th>Case</th>
<th>BNN Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD063/13</td>
<td>19686</td>
</tr>
<tr>
<td>SD024/15</td>
<td>26495</td>
</tr>
<tr>
<td>SD056/14</td>
<td>24527</td>
</tr>
<tr>
<td>SD005/16</td>
<td>28410</td>
</tr>
<tr>
<td>SD010/16</td>
<td>28771</td>
</tr>
</tbody>
</table>

MRC numbers and associated BNN numbers.
**Supplementary Figure 1.** Distribution of non-phosphorylated and phosphorylated α-synuclein in dementia with Lewy bodies and controls.

A Representative images of brain sections of a case with dementia with Lewy bodies and a control case stained with antibodies against non-phosphorylated α-synuclein (red) and p-α-synuclein (green). Each image is a maximum intensity projection of 20 consecutive sections. B Three dimensional representation of non-phosphorylated alpha-synuclein (red) and p-α-synuclein (green) aggregates found in DLB cases. An inset of the low magnification image is shown on the right. Abbreviations: DLB, dementia with Lewy bodies. Scale bar in A, 10µm; in B, 5µm (left) and 2µm (right).
Supplementary Figure 2. Segmentation and co-localization examples.

<table>
<thead>
<tr>
<th>A</th>
<th>Figure 2 segmentation example</th>
</tr>
</thead>
<tbody>
<tr>
<td>LN</td>
<td><img src="image1" alt="Segmentation example" /></td>
</tr>
<tr>
<td>SA</td>
<td><img src="image2" alt="Segmentation example" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B</th>
<th>Other pre-synaptic p-α-synuclein segmentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>LN</td>
<td><img src="image3" alt="Segmentation example" /></td>
</tr>
<tr>
<td>SA</td>
<td><img src="image4" alt="Segmentation example" /></td>
</tr>
</tbody>
</table>

A Three dimensional representations of the images shown in Figure 2 as well as synaptograms representing six 70nm consecutive sections (from left to right and top to bottom) of a Lewy neurite (LN) or a small aggregate (SA) (green) colocalizing with synaptophysin (red) pointed by the arrowheads. Both the raw and segmented images are shown. B 3D examples of other segmented Lewy neurites and small aggregates. Synaptograms on the bottom-right represent a magnification of the pointed area.

Abbreviations: LN, Lewy neurite; SA, Small aggregate. Scale bars in A and B, 2µm.
Supplementary Figure 3. Pre-synaptic localization of p-α-synuclein and synapsin I in DLB.

A Three dimensional reconstruction of 20 consecutive sections from a DLB case. P-α-synuclein (green), synaptophysin (red) and synapsin I (blue) are shown. An inset of the low magnification image is shown on the right. Arrowheads indicate objects with co-localization of all three markers. Scale bars 10µm (left) and 2µm (right).